ICBP Phase 1 Researchers

<table>
<thead>
<tr>
<th>Research question</th>
<th>Lead researchers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Survival Benchmark 1995-2007 (4 cancer types)</td>
<td>Michel Coleman, Sarah Walters, Bernard Rachet</td>
</tr>
<tr>
<td>Public awareness, attitudes and beliefs about cancer</td>
<td>Jane Wardle, Lindsay Forbes, Alice Simon</td>
</tr>
<tr>
<td>Role of primary care doctors and health systems in diagnosis</td>
<td>Peter Rose, Greg Rubin, Sarah Brown</td>
</tr>
<tr>
<td>Measuring time intervals and pathways from diagnosis to treatment</td>
<td>Peter Vedsted, David Weller, Usha Menon</td>
</tr>
<tr>
<td>Exploring the impact of registry practices and comorbidity on short term outcomes</td>
<td>Michael Eden, Eva Morris, Margreet Lüchtenborg</td>
</tr>
</tbody>
</table>

ICBP Phase 1 Working groups

Survival benchmark 1995-2007

**Research leaders:** Jan Adolfsson (Karolinska University Hospital, Stockholm, Sweden); Heather Bryant (Canadian Partnership Against Cancer, Toronto, Canada); Michael Coory (Cancer Council Victoria, Melbourne, Australia); David Forman (International Agency for Research on Cancer, Lyon, France); Marianne L Gjerstorff (Danish Cancer Registry, Copenhagen, Denmark); Tom Borge Johannesen (Norwegian Cancer Registry, Oslo, Norway); Mats Lambe (Karolinska Institutet, Stockholm, Sweden); David Meechan (Trent Cancer Registry, Sheffield, UK); Richard Middleton (Northern Ireland Cancer Registry, Belfast, UK); Janey Shin (Canadian Partnership Against Cancer, Toronto, Canada); John Steward (Welsh Cancer Intelligence and Surveillance Unit, Cardiff, UK); Elizabeth Tracey (Cancer Institute NSW, Sydney, Australia).

**Cancer registries:** Juanita Hatcher, Carol Russell (Alberta Health Services, Edmonton, Canada); Andy Coldman, Mark Elwood, David Levy, Colleen E McGahan (British Columbia Cancer Agency, Vancouver, Canada); Dhali Dhalwal, Donna Turner (CancerCare Manitoba, Winnipeg, Canada); Loraine Marrett, John McLaughlin, Kamini Milnes, Diane Nishri, Michael Sherar (Cancer Care Ontario, Toronto, Canada); Gerda Engholm (Danish Cancer Society, Copenhagen, Denmark); Eva J Morris, James Thomas (Northern and Yorkshire Cancer Registration and Information Service, Leeds, UK); Karen Linklater (Thames Cancer Registry, London, UK); Rebecca Elleray, David Meechan, Andy Smith (Trent Cancer Registry, Sheffield, UK); Gill Lawrence (West Midlands Cancer Intelligence Unit, Birmingham, UK); Finian Bannon, Colin Fox (Northern Ireland Cancer Registry, Belfast, UK); Ceri White (Welsh Cancer Intelligence and Surveillance Unit, Cardiff, UK).

**Clinical committee:** Jonas Bergh (Karolinska Institutet, Stockholm, Sweden); John Boyages (Westmead Breast Cancer Institute, Sydney, Australia); Michel Boyer (Sydney Cancer Centre, Sydney, Australia); John Butler (Department of Health, London, UK); Peter Clark (Clatterbridge Centre for Oncology, Liverpool, UK); Bill Evans (Juravinski Cancer Centre at Hamilton Health Sciences, Cancer Care Ontario, Toronto, Canada); Hilary Fielder (Velindre NHS Trust, Cardiff, UK); Tony Fields (Alberta Health Services, Edmonton, Canada); Paul Finan (Leeds Teaching Hospitals NHS Trust, Leeds, UK); Tommy Fornander, Södersjukhuset, Stockholm, Sweden); Neville Hacker (Royal Hospital for Women, Sydney, Australia); Louise Hanna (Velindre NHS Trust, Cardiff, UK); Thomas Hogberg (Skåne University Hospital, Lund, Sweden); Charlotte Hosbond (National Board of Health, Copenhagen, Denmark); Karl Kölbeck (Karolinska University Hospital, Stockholm, Sweden); Martin Lee (University Hospitals Coventry and Warwickshire NHS Trust, Coventry, UK); Peter Barrett Lee (Velindre NHS Trust, Cardiff, UK); Jason Lester (Velindre NHS Trust, Cardiff, UK); Mark Levine (McMaster University, Hamilton, Canada); Gudrun Lindmark (Skåne University Hospital, Malmö-Lund, Sweden); Tim Maughan (Velindre NHS Trust, Cardiff, UK); Usha Menon (University College London, London, UK); Ian Moneypenny (Cardiff & Vale NHS Trust, Cardiff, Wales, UK); Andy Nordin (East Kent University Hospitals, Canterbury, UK); Julietta Patrick (NH Cancer Screening, Sheffield, UK); Mick Peake (Department of Respiratory Medicine, Leicester, UK); Andrew Radcliffe (Llandough Hospital, Penarth, UK); Barry Rosen (University of Toronto, Toronto, Canada); Annika Sjövall (Karolinska University Hospital, Stockholm, Sweden); Allan Spigelman (University of New South Wales, Sydney, Australia); Gunnar Wagenius (Uppsala University Hospital, Uppsala, Sweden); Fredrik Wärnberg (Uppsala University Hospital, Uppsala, Sweden); Michael Williams (Addenbrooke’s, Cambridge, UK); Ian Williamson (Royal Gwent Hospital, Newport, UK).
Central Analytic Team (Cancer Research UK Cancer Survival Group, London School of Hygiene and Tropical Medicine, London, UK): Claudia Allemani (also Analytical Epidemiology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy), Michiel P Coleman, Libby Ellis, Camille Maringe, Ula NUR, Manuela Quaresma, Bernard Rachet, Sarah Walters.

Epidemiology Reference Group: Bruce Armstrong (University of Sydney, Sydney, Australia); Paul Dickman (Karolinska Institutet, Stockholm, Sweden); Paul Lambert (University of Leicester, Leicester, UK); Dianne O’Connell (Cancer Council New South Wales, Sydney, Australia); Milena Sant (Istituto Nazionale dei Tumori, Milan, Italy); Hannah Weir (Centers for Disease Control and Prevention, Atlanta, USA).

Public awareness, attitudes and beliefs about cancer
Michael Donnelly (Queen’s University Belfast, Belfast, UK); David Donnelly (Queen’s University Belfast, Belfast, UK); Anette Fischer Pedersen (Aarhus University, Aarhus, Denmark); Deb Keen (Canadian Partnership Against Cancer, Toronto, Canada); Chris Roberts (Welsh Cancer National Specialist Advisory Group, Cardiff, UK); James Kite (Cancer Institute New South Wales, New South Wales, Australia); Blythe O’Hara (Cancer Institute New South Wales, New South Wales, Australia); Donna Perez (Cancer Institute New South Wales, New South Wales, Australia); Lisa Petermann (Canadian Partnership Against Cancer, Toronto, Canada); Chris Roberts (Welsh Cancer National Specialist Advisory Group, Cardiff, UK); Melanie Wakefield (Cancer Council Victoria, Victoria, Australia); Christian Wulff (Aarhus University, Aarhus, Denmark).

Role of primary care doctors and health systems in diagnosis
Andriana Barisic (Cancer Care Ontario, Toronto, Ontario, Canada); Martin Dawes (University of British Columbia, Vancouver, Canada); Diana Dawes (University of British Columbia, Vancouver, Canada); Mark Elwood (University of Auckland, Auckland, New Zealand); Kirsty Forsdike (Department of General Practice, Victoria, Australia); Eva Grunfeld (University of Toronto, Ontario, Canada); Nigel Hart (Queen’s University Belfast, Belfast, UK); Breann Hawrylyk (Cancer Care Manitoba, Winnipeg, Canada); Gerald Konrad (University of Manitoba, Winnipeg, Canada); Anne Kari Knudsen (Norwegian University of Science and Technology, Trondheim, Norway); Magdalena Lagerlund (Karolinska Institute, Stockholm, Sweden); Claire McAulay (University of Sydney, Sydney, Australia); Jin Mou (University of British Columbia, Vancouver, Canada). Richard D Neal (Bangor University, Wrexham, UK); Marie Pirotta (Department of General Practice, Carlton, Australia); Jeffrey Sisler (University of Manitoba, Winnipeg, Canada); Berit Skjødeberg Toftegaard (Aarhus University, Aarhus, Denmark); Hans Thulesius (Lund University, Lund, Sweden); Peter Vedsted (Aarhus University, Aarhus, Denmark); David Weller (University of Edinburgh, Edinburgh, UK); Jane Young (The University of Sydney, Australia).

Academic Reference Group: Jon Emery (University of Melbourne and University of Western Australia, Australia); Niek de Wit (University Medical Centre, Utrecht, The Netherlands); Roger Jones (King's College, London, UK); Jean Muris (Maastricht University, The Netherlands); Frede Olesen (University of Aarhus, Denmark).

Measuring time intervals and pathways from diagnosis to treatment
Sigrun Saur Almberg (Norwegian University of Science and Technology, Trondheim, Norway); Chantelle Anandar (University of Edinburgh, Edinburgh, UK); Andriana Barisic (Cancer Care Ontario, Toronto, Canada); Jackie Boylan (Queen's University Belfast, Belfast, UK); Conan Donnelly (Queen’s University Belfast, Belfast, UK); Evangelia Ourania Fourkala (University College London, London, London, UK); Alina Zaloumina Falborg (Aarhus University, Aarhus, Denmark); Anna Gavin (Queen's University Belfast, Belfast, UK); Eva Grunfeld (University of Toronto, Ontario, Canada); Victoria Hammersley (University of Edinburgh, Edinburgh, UK); Breann Hawrylyk (Cancer Care Manitoba, Winnipeg, Canada); Therese Kearney (Queen’s University Belfast, Belfast, UK); Jacqueline Kelly (Queen’s University Belfast, Belfast, UK); Anne Kari Knudsen (Norwegian University of Science and Technology, Trondheim, Norway); Mats Lambe (Karolinska Institutet, Stockholm, Sweden); Rebecca Law (Bangor University, Wrexham, UK); Yulan Lin (Norwegian University of Science and Technology, Trondheim, Norway); Martin Malmberg (Lund University Hospital, Lund, Sweden); Usha Menon (University College London, London, UK); Kerry Moore (Queen's University Belfast, Belfast, UK); Richard D Neal (Bangor University, Wrexham, UK); Donna Turner (Cancer Care Manitoba, Winnipeg, Canada); Peter Vedsted (Aarhus University, Aarhus, Denmark); David Weller (University of Edinburgh, Edinburgh, UK); Vicki White (Cancer Council Victoria, Melbourne, Australia); Henry Jensen (Aarhus University, Aarhus, Denmark).

Academic Reference Group: Jan Willem Coebergh (Erasmus Universiteit Rotterdam, Rotterdam, the Netherlands); Jon Emery (University of Melbourne and University of Western Australia, Australia); Stefan Bergström (Department of Oncology, Gävle, Sweden); Monique E van Leerdam (Erasmus MC University Medical Centre, the Netherlands); Marie-Louise Essink-Bot (Academic Medical Centre, Amsterdam University, the Netherlands); Una MacLeod (Hull-York Medical School, UK).
Exploring the impact of registry practices and comorbidity on short term outcomes

Mike Eden (Public Health England, London, UK); Michelle Griffin (Public Health England, London, UK); Jem Rashbass (Public Health England, London, UK); Eva Morris (Leeds Institute of Cancer and Pathology, Leeds, UK); Mick Peake (Public Health England, London, UK); Margreet Luchtenborg (King’s College London, London, UK); Victoria Coupland (Public Health England, London, UK); Daniela Tateru (Public Health England, London, UK); Deirdre Fitzpatrick (Queen’s University Belfast, Belfast, UK); Conan Donnelly (Queen’s University Belfast, Belfast, UK); Dyfed W Huws (Public Health Wales, Cardiff, UK); Janet Warlow (Welsh Cancer Intelligence & Surveillance Unit, Cardiff, Wales); Ceri White (Welsh Cancer Intelligence & Surveillance Unit, Cardiff, Wales); David H Brewster (Scottish Cancer Registry, Edinburgh, UK); Andy Deas (Scottish Cancer Registry, Edinburgh, UK); Anne-Kari Knudsen (Norwegian University of Science and Technology, Trondheim, Norway); Yulan Lin (Norwegian University of Science and Technology, Trondheim, Norway); Bjørn Møller (Cancer Registry of Norway, Oslo, Norway); Donna Turner (Cancer Care Manitoba, Winnipeg, Canada); Craig Earle (Cancer Care Ontario, Toronto, Canada); Mary-Jane King (Cancer Care Ontario, Toronto, Canada); Diane Nishri (Cancer Care Ontario, Toronto, Canada); Lorraine Shack (Alberta Health Services, Calgary, Canada); Roger Milne (Cancer Council Victoria, Melbourne, Australia); Luc te Marvelde (Cancer Council Victoria, Melbourne, Australia); Deborah Baker (Cancer Institute NSW, Sydney, Australia); Richard Walton (Cancer Institute NSW, Sydney, Australia).

Academic Reference Group: Henrik Moller (Kings College London, UK); Paul Lambert (University of Leicester, UK); Paul Dickman (Karolinska Institute, Sweden); Hannah Weir (Centre for Disease Control and Prevention, Atlanta, USA).